{
  "docId": "019de077-2e43-774b-aad6-58a03a29d59d",
  "docSlug": "207557819f8810b573d3e2a3179a9bac",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 55 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 55,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "comparison_table",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 28,
  "notes": "The table compares safety data across various categories of adverse events, including grade 3/4, serious AEs, and treatment-related outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-2e43-774b-aad6-58a03a29d59d/30",
  "deckHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d",
  "deckJsonHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d.json",
  "deckAnchorHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "The safety population includes all patients who received treatment. 1. Recommended timeframe for RC was within 56 days after the last dose of NAC. 2. In patients who started adjuvant durvalumab. 3. Investigator-assessed causality. The overall study period includes AEs that occurred between the first dose of study treatment, and whichever occurred first: 1) 90 days after the last dose of treatment, surgery, or last adjuvant visit; 2) date of first dose of subsequent anti-cancer therapy; or 3) data cutoff date. Data cutoff 29 Apr 2024. Powles TB et al. Abstract LBA5 presented at the European Society of Medical Oncology 2024.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6b7f4ea-39da-4b40-9f38-c3e5254a9c0c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.92,
        "x": 0.04,
        "y": 0.245
      },
      "kind": "table",
      "text": "Comparison of AE rates between Imfinzi arm (N=530) and Comparator arm (N=526)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d896543-3f8e-4eb8-9d93-ab98252b144b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Imfinzi regimen generally well tolerated",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22e1f8c3-b501-4ae1-9262-0217d7834fb1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 30,
      "from": 26,
      "beatId": "617689da-c69b-43c7-8222-b2a08def2699",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents the positive results of the NIAGARA trial.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 35,
      "from": 22,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e1d82b9f-ab34-4351-be54-5e9df327f1c4",
      "evidence": "The document highlights the high unmet need and presents NIAGARA as a solution.",
      "position": 0,
      "objective": "What is the cost of not addressing the unmet need in muscle-invasive bladder cancer?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}